Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 8/20 | 0.57 |
| ▸ | ITGA4 | P13612 | 8/20 | 0.57 |
| ▸ | MAOB | P27338 | 2/20 | 0.49 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL71415 | 0.91 | ITGB1 (0.60) | ITGB1ITGA4MAOBS1PR2LMNA | |
| SCHEMBL3579447 | 0.87 | ITGB1 (0.56) | ITGB1ITGA4MAOBS1PR2LMNA | |
| SCHEMBL2431865 | 0.85 | ITGB1 (0.57) | ITGB1ITGA4MAOBLMNAMITF | |
| SCHEMBL91608 | 0.83 | MAOB (0.54) | ITGB1ITGA4MAOBLMNAMITF | |
| SCHEMBL14591764 | 0.81 | ITGB1 (0.57) | ITGB1ITGA4MAOBS1PR2LMNA | |
| SCHEMBL2435704 | 0.80 | ITGB1 (0.51) | ITGB1ITGA4LMNAMITFALDH1A1 | |
| SCHEMBL14491728 | 0.80 | KDM4E (0.48) | ITGB1ITGA4S1PR2ALDH1A1NPSR1 | |
| SCHEMBL4946444 | 0.79 | MAOB (0.58) | MAOBLMNAMITFALDH1A1MAPT | |
| SCHEMBL92369 | 0.79 | RAB9A (0.64) | MAOBLMNAMITFALDH1A1MAPT | |
| SCHEMBL2429977 | 0.79 | ITGB1 (0.50) | ITGB1ITGA4MAPTKMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130065882-A1 | VLA-4 inhibitory drug | MACHINAGA NOBUO (JP) | 2013-03-14 | — | — | US | disclosed |
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-06-21 | — | — | US | disclosed |
| EP-1650205-B1 | CYCLOHEXANECARBOXYLIC ACID COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2012-04-25 | — | — | EP | disclosed |
| US-8129366-B2 | VLA-4 inhibitory drug | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-06 | — | — | US | disclosed |
| EP-1346982-B1 | VLA-4 INHIBITORS | DAIICHI SEIYAKU CO (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-7893279-B2 | Cyclohexanecarboxylic acid compound | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-02-22 | — | — | US | disclosed |
| US-7691894-B2 | Cyclohexanecarboxylic acid compound | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-06 | — | — | US | disclosed |
| US-20100076202-A1 | METHOD FOR PRODUCING PYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-03-25 | — | — | US | disclosed |
| US-20100076202-A1 | METHOD FOR PRODUCING PYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-03-25 | — | — | US | disclosed |
| US-20100076202-A1 | METHOD FOR PRODUCING PYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-03-25 | — | — | US | disclosed |
| US-20070105935-A1 | Process for producing pyrrolidine derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1757602-A1 | VLA-4 INHIBITOR | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| EP-1698611-A1 | PROCESS FOR PRODUCING PHENYLACETIC ACID DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
| EP-1698621-A1 | METHOD FOR PRODUCING PYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-09-06 | — | — | EP | disclosed |
| EP-1650205-A1 | CYCLOHEXANECARBOXYLIC ACID COMPOUND | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-04-26 | — | — | EP | disclosed |
| US-20040110945-A1 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
| EP-1346982-A1 | VLA-4 INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | ITGB1 16/4885ITGA4 3/4885MAOB 2184/4885 |
| US-20130065882-A1 | VLA-4 inhibitory drug | VCAM1, ITGB4, ITGA4 | ITGB1 13/4885ITGA4 3/4885MAOB 2935/4885 |
| US-20100076202-A1 | METHOD FOR PRODUCING PYRROLIDINE DERIVATIVE | ALDH18A1, PLAAT4, ACSL4 | ITGB1 820/4885ITGA4 28/4885MAOB 2226/4885 |
| US-20040110945-A1 | Vla-4 inhibitors | VCAM1, ITGA1, ITGB4 | ITGB1 5/4885ITGA4 4/4885MAOB 2580/4885 |
| US-20070105935-A1 | Process for producing pyrrolidine derivative | ACSL4, ALDH18A1, LTA | ITGB1 2327/4885ITGA4 287/4885MAOB 3101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.